News

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
Sandoz is a global leader in the generics and biosimilars sector. Click here to read why I think spinning off SDZNY stock was a good move by Novartis.
We have successfully executed the spin-off of Sandoz, allowing us to fully focus on high-value innovative medicines,” Novartis CEO Vas Narasimhan, MD said in a statement. “Our growth drivers, ...
On Oct 4, 2023, Novartis announced it has completed its plan to spin-off Sandoz, its generics and biosimilars business, into an independent company. The spin-off took place through a dividend-in-kind ...
Summary Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off.
Sandoz has completed its separation from Novartis, with the business now continuing as an independent spin-off company. The separation allows Novartis to fully focus its attention on innovative ...
Sandoz starts share trading on SIX Swiss Exchange as independent company after 100 percent spin-off from Novartis ...
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
The Spin-off of Sandoz enables Novartis to complete its transformation to become a leading, focused medicines company. With capital allocation and management attention fully focused on innovative ...
Novartis expects the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs, will commence on Oct. 4.
Novartis has officially confirmed it’s spin-off, Sandoz, with trading of new Sandoz Group AG shares and American Depositary Receipts (ADRs) to commence on Oct. 4. Expected to be listed and traded on ...